Liraglutide still a ‘decent market’ despite Novo’s price moves: Siddharth Mittal, Biocon

Liraglutide still a ‘decent market’ despite Novo’s price moves: Siddharth Mittal, Biocon

Biocon CEO Siddharth Mittal outlines the company's strategy in the competitive GLP-1 market. Focusing on liraglutide's launch in the US and Europe, he highlights opportunities in emerging markets. While semaglutide is a longer-term play, Biocon is actively …

As competition intensifies in the global GLP-1 market, the spotlight has shifted to how generic players are positioning themselves amid pricing pressures from innovators. In an interaction with ET No… [+5051 chars]

Related Posts

About FHMnews

What is FHMnews?

FHMnews is the result of a rebellion that transcended frustration. Look around you. As PK puts it, the people in this circle think one thing, say another, and do another. We shook up all three, confined within one circle, and decided to write as they think and speak. News, views, and everything beyond.

FHMnews is the country's first "new age" English news website. It's modern in its language, attitude, and news standards. It features selected news stories from the day, but with 360-degree coverage. It offers a complete report and analysis of each story, along with additional features like quizzes, polls, memes, and videos.

FHMnews Ltd.

E-43, Phase 8
Sahibzada Ajit Singh Nagar,
Punjab, 160071

Get In Touch With Us

© Copyright FHMnews
Liraglutide still a ‘decent market’ despite Novo’s price moves: Siddharth Mittal, Biocon - FHMnews